Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.
AMA J Ethics. 2018;20(9):E841-848. doi:
10.1001/amajethics.2018.841.
The Holocaust and the racial hygiene doctrine that helped rationalize it still overshadow contemporary debates about using gene editing for disease prevention.
AMA J Ethics. 2021;23(1):E49-54. doi:
10.1001/amajethics.2021.49.
Dr Chad M. Teven joins Ethics Talk to unravel some current and a few hoped-for surgical applications of AI and to model for us how we should be critically engaging with AI surgical research and scholarship.
Dr Emma Cooke joins Ethics Talk to discuss her article, coauthored with Dr Holland Kaplan: “How Should Technology-Dependent Patients’ Care Be Managed Collaboratively to Avoid Turfing?”
Anne Drapkin Lyerly, MD, MA and Ruth R. Faden, PhD, MPH
Participation in a research study—in which there are rigorous standards and close monitoring—may be a safer context for the use of medications in pregnancy than the clinical setting, where the evidence base is lacking.
Whether or not to inform patients of off-label drug prescribing has been the subject of heated debate for a long time, with convincing arguments made on both sides of the issue and no consensus reached.